{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Acrivon Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ACRV"},"Address":{"label":"Address","value":"480 ARSENAL WAY,SUITE 100, WATERTOWN, Massachusetts, 02472, United States"},"Phone":{"label":"Phone","value":"6172078979.0"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer."},"CompanyUrl":{"label":"Company Url","value":"https://www.acrivon.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Eric J. Devroe","title":"Chief Operating Officer"},{"name":"Jean-Marie Cuillerot","title":"Chief Medical Officer"},{"name":"Karl Hsu","title":"Senior Vice President-Clinical Development"},{"name":"Monica Phadnis","title":"Senior Vice President-Clinical Operations"},{"name":"Peter Blume-Jensen","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}